WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Epigenetics

Background:

• WDR5 is a nuclear protein involved in epigenetic regulation and mitosis.
• WDR5 is a target for anti-cancer therapies, with inhibitors and degraders in preclinical development.
• Current WDR5 inhibitors are thought to function as epigenetic modulators by targeting histone methylation.

Purpose of the Study:

• To challenge the prevailing notion of WDR5 inhibitors as epigenetic modulators.
• To propose a unified model for WDR5 inhibitor action.
• To clarify the mechanism of WDR5 inhibitors for improved anti-cancer therapy.

Main Methods:

• Review of existing literature on WDR5 function and inhibitor mechanisms.
• Analysis of contemporary data regarding WDR5 inhibitor activity.
• Development of a new mechanistic model for WDR5 inhibitor action.

Main Results:

• The premise of WDR5 inhibitors acting as epigenetic modulators is not supported by current evidence.
• A unified model posits WDR5 inhibitors function as ribosome-directed agents.
• This ribosome-targeting mechanism explains the anti-cancer properties of WDR5 inhibitors.

Conclusions:

• WDR5 inhibitors' anti-cancer effects stem from ribosome targeting, not epigenetic modulation.
• Revising the understanding of WDR5 inhibitors' mechanism is crucial for therapeutic development.
• Exploiting WDR5 inhibitors as ribosome-directed therapies offers new avenues for cancer treatment.